Director, HEOR & Value Evidence

Telix Pharmaceuticals is a dynamic, fast-growing radiopharmaceutical company with offices in Australia (HQ), Belgium, Japan, Switzerland, and the United States. Our mission is to deliver on the promise of precision medicine through targeted radiation. At our core, we exist to create products that seek to improve the quality of life for people living with cancer and rare diseases. You will be supporting the international roll-out of our approved prostate cancer imaging agent and helping us to advance our portfolio of late clinical-stage products that address significant unmet need in oncology and rare diseases. 

See Yourself at Telix

The Director, HEOR & Value Evidence is a highly analytical and strategically minded Health Economics and Outcomes Research (HEOR) leader responsible for shaping and delivering the value narrative across a diverse portfolio of diagnostic and therapeutic assets. This role sits at a critical crossroads between clinical development and commercial success, transforming scientific data into persuasive, payer-relevant evidence that drives access, reimbursement, and long-term market differentiation. As a key member of the over-arching Value & Access organization, the Director will lead the generation, and translation of robust economic and outcomes evidence required to secure and sustain optimal reimbursement. In parallel, this individual will serve as a clinical and technical subject matter expert, partnering closely with Market Access and Payer teams to support high-stakes external engagements with payers, policymakers, and other senior stakeholders.

Key Accountabilities:

Evidence Generation & Study Design

• Clinical Trial Integration: Collaborate with Clinical Development to incorporate HEOR endpoints into Phase II–IV protocols to ensure data supports "Value-Based" narratives. 
• RWE & Registries: Lead the design and execution of Real-World Evidence (RWE) studies and patient registries to characterize disease burden, treatment patterns, and long-term outcomes. 
• Diagnostic Utility: For diagnostic assets, develop studies that demonstrate clinical utility—showing how the test specifically changes patient management and improve outcomes.  

Clinical & Payer Field Support

• Payer Presentations: Assist in the delivery of Pre-approval Information Exchanges (PIE), and Value Proposition Support, providing the clinical and health-economic backbone for early and product launch discussions with payers and health systems translating complex HEOR data into compelling clinical narratives.  
• Expert Resource: Act as the clinical subject matter expert during payer meetings to address deep-dive technical questions regarding study design, clinical utility, and patient outcomes.